AriBio

Fineline Info & Tech (Flcube.com) provides you with comprehensive information about AriBio details on the company, its pharmaceuticals, policies, deals, healthcare enterprises, research and development, hospitals, legal patents, and internet healthcare. More information about AriBio please access flcube.com

Fineline Info & Tech (Flcube.com) provides you with comprehensive information about AriBio details on the company, its pharmaceuticals, policies, deals, healthcare enterprises, research and development, hospitals, legal patents, and internet healthcare. More information about AriBio please access flcube.com

Xiangxue Pharma's XLS-103 Wins NMPA Clinical Trial Approval for KRAS G12V–Positive Advanced Colorectal Cancer – Proprietary TCR-T Cell Therapy Expands to Third Tumor Type in China
CompanyDrug

Xiangxue Pharma’s XLS-103 Wins NMPA Clinical Trial Approval for KRAS G12V–Positive Advanced Colorectal Cancer – Proprietary TCR-T Cell Therapy Expands to Third Tumor Type in China

Guangzhou Xiangxue Pharmaceutical Co., Ltd ("XPH") (SHE: 300147) announced that its investigational TCR-T cell therapy candidate XLS-103 has received clinical trial approval from China's National Medical Products Administration (NMPA) for…

Innovent's Sintilimab Plus Nogileucel (GC101) Melanoma NDA Accepted by NMPA – Backed by 57% Progression Risk Reduction in MIZAR-003

Innovent’s Sintilimab Plus Nogileucel (GC101) Melanoma NDA Accepted by NMPA – Backed by 57% Progression Risk Reduction in MIZAR-003

WuXi AppTec Q3 Revenue Jumps 38% as Backlog Hits RMB 76.74 Billion – Full-Year Guidance Raised

WuXi AppTec Q3 Revenue Jumps 38% as Backlog Hits RMB 76.74 Billion – Full-Year Guidance Raised

Empowering Chinese Pharma’s Global Expansion

Leverage premier media reach to connect your pipeline with global partners. Contact us to drive your international growth today.
Explore Now
Fosun Pharma Secures Global Rights to AriBio's Alzheimer's Drug AR1001 in $240M Deal – PDE-5 Inhibitor Shows Promise in Phase III
CompanyDeals

Fosun Pharma Secures Global Rights to AriBio’s Alzheimer’s Drug AR1001 in $240M Deal – PDE-5 Inhibitor Shows Promise in Phase III

CompanyDeals

AriBio Expands Alzheimer’s Drug AR1001 Licensing Deal with Samjin to Include China

CompanyDrug

AriBio Files for Phase III Clinical Trial Approval in China for Alzheimer’s Drug AR1001